Literature DB >> 18218608

Incidence of dementia in long-term hormone users.

Diana B Petitti1, Valerie C Crooks, Vicki Chiu, J Galen Buckwalter, Helena C Chui.   

Abstract

Results from epidemiologic studies of postmenopausal hormone use and dementia have been conflicting. Investigators from the Women's Health Initiative Memory Study reported that the incidence of dementia in women aged >/=65 years assigned to hormone use was increased. Here the authors report results from a prospective cohort study of 2,906 dementia-free women (1,519 hormone users and 1,387 hormone nonusers) aged > or =75 years who were recruited from a Southern California health plan in 1999 and followed through 2003. Cognitive status was assessed annually using the Telephone Interview of Cognitive Status-modified, supplemented by the Telephone Dementia Questionnaire and medical record review. The mean self-reported age at initiation of hormone use was 48.3 years for users of estrogen alone (n = 1,072) and 54.9 years for users of estrogen plus progestin (n = 447); self-reported mean durations of hormone use were 30.5 years and 23.2 years, respectively. There were 283 incident dementia cases identified during follow-up. After adjustment for age, education, and medical history, hazard ratios for incident dementia were 1.34 (95% confidence interval: 0.95, 1.89) in estrogen/progestin users and 1.23 (95% confidence interval: 0.94, 1.59) in estrogen users. These findings do not provide support for an effect of estrogen or estrogen/progestin use in preventing dementia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18218608     DOI: 10.1093/aje/kwm362

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  11 in total

1.  Timing of hormone therapy and dementia: the critical window theory revisited.

Authors:  Rachel A Whitmer; Charles P Quesenberry; Jufen Zhou; Kristine Yaffe
Journal:  Ann Neurol       Date:  2010-11-12       Impact factor: 10.422

2.  Cognitive benefits of hormone therapy: cardiovascular factors and healthy-user bias.

Authors:  Whitney Wharton; Maritza Dowling; Christine M Khosropour; Cynthia Carlsson; Sanjay Asthana; Carey E Gleason
Journal:  Maturitas       Date:  2009-10-29       Impact factor: 4.342

Review 3.  Oophorectomy, estrogen, and dementia: a 2014 update.

Authors:  Walter A Rocca; Brandon R Grossardt; Lynne T Shuster
Journal:  Mol Cell Endocrinol       Date:  2014-02-05       Impact factor: 4.102

4.  Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline.

Authors:  Jae H Kang; Francine Grodstein
Journal:  Neurobiol Aging       Date:  2010-11-30       Impact factor: 4.673

Review 5.  Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity.

Authors:  Walter A Rocca; Brandon R Grossardt; Lynne T Shuster
Journal:  Brain Res       Date:  2010-10-18       Impact factor: 3.252

Review 6.  Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease.

Authors:  Jacqueline O'Brien; John W Jackson; Francine Grodstein; Deborah Blacker; Jennifer Weuve
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

7.  Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.

Authors:  J Ryan; I Carrière; J Scali; J F Dartigues; C Tzourio; M Poncet; K Ritchie; M L Ancelin
Journal:  Neurology       Date:  2009-11-24       Impact factor: 9.910

Review 8.  Endogenous and exogenous estrogen, cognitive function, and dementia in postmenopausal women: evidence from epidemiologic studies and clinical trials.

Authors:  Elizabeth Barrett-Connor; Gail A Laughlin
Journal:  Semin Reprod Med       Date:  2009-04-28       Impact factor: 1.303

Review 9.  Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease.

Authors:  Roberta Diaz Brinton
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

10.  Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

Authors:  Alfredo Robles
Journal:  Open Neurol J       Date:  2009-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.